- Home
- HBB vs TNGX Comparison
HBB vs TNGX Comparison
Compare HBB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- TNGX
- Stock Information
- Founded
- HBB 1904
- TNGX 2014
- Country
- HBB United States
- TNGX United States
- Employees
- HBB N/A
- TNGX N/A
- Industry
- HBB Home Furnishings
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- TNGX Health Care
- Exchange
- HBB Nasdaq
- TNGX Nasdaq
- Market Cap
- HBB 242.8M
- TNGX 248.2M
- IPO Year
- HBB 2017
- TNGX N/A
- Fundamental
- Price
- HBB $18.02
- TNGX $2.21
- Analyst Decision
- HBB
- TNGX Strong Buy
- Analyst Count
- HBB 0
- TNGX 6
- Target Price
- HBB N/A
- TNGX $12.20
- AVG Volume (30 Days)
- HBB 45.9K
- TNGX 3.5M
- Earning Date
- HBB 04-30-2025
- TNGX 05-12-2025
- Dividend Yield
- HBB 2.63%
- TNGX N/A
- EPS Growth
- HBB 18.18
- TNGX N/A
- EPS
- HBB 2.43
- TNGX N/A
- Revenue
- HBB $659,788,000.00
- TNGX $40,990,000.00
- Revenue This Year
- HBB N/A
- TNGX N/A
- Revenue Next Year
- HBB N/A
- TNGX N/A
- P/E Ratio
- HBB $7.53
- TNGX N/A
- Revenue Growth
- HBB 5.46
- TNGX 10.09
- 52 Week Low
- HBB $13.25
- TNGX $1.03
- 52 Week High
- HBB $31.78
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- HBB 53.04
- TNGX 62.72
- Support Level
- HBB $18.05
- TNGX $1.93
- Resistance Level
- HBB $19.00
- TNGX $2.67
- Average True Range (ATR)
- HBB 0.68
- TNGX 0.39
- MACD
- HBB 0.15
- TNGX 0.07
- Stochastic Oscillator
- HBB 56.99
- TNGX 55.38
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.